Zealand Pharma — April 2023
-
-
Jeg er på vej hjem og på Schipol lufthavn lige nu men har nu fået læst lidt sf artiklen og jeg må dele lidt her:
-
Zealand Pharma is working with the investment bank to identify potential partners for a key rare disease treatment targeting short bowel syndrome, as well as for some dasiglucagon-based medications, the people said. The process may end up leading to a full sale of the company, which has previously been studied by large pharmaceutical firms, they said.
-
Og lidt senere “ Deliberations are at an early stage and there’s no certainty they will lead to a transaction, the people said, asking not to be identified as the matter is private. A representative for the company declined to comment beyond previous statements, while a spokesperson for Centerview didn’t immediately respond to a request for comment.”
-
Det bliver meget interessant hvordan den åbner i morgen.
-
Hmm…det var en interessant nyhed
HVIS jeg var short, så ville jeg se at få “ræven” ud Ellers KAN det blive dyrt -
"In March, Pfizer Inc. agreed to buy cancer-drug maker Seagen Inc. for $43 billion. Amgen Inc. struck a $27.8 billion deal in December for autoimmune disease drugmaker Horizon Therapeutics Plc in a bid to boost sales."
"Apellis Pharmaceuticals Inc., a biotech firm focused on rare diseases and ophthalmology, is drawing takeover interest from larger drugmakers, Bloomberg News reported in March"
-
Centerview Partners LLC (transactions):
-
-
Zealand Pharma gennemfører et vellykket accelereret bookbuilding-udbud til en værdi af 1,5 mia. kr.
Plesner er glade for at havde bistået vores mangeårige klient Zealand Pharma i forbindelse med en kapitalforhøjelse ...
(12. april 2023)
-
En stor tak til dig @EliotSpitzer for at have fundet denne Centerview-Partners-nyhed fra Bloomberg.
-
Lau fra Millionær klubben undret sig over ZP ‘s emission. Han mente de var tidligt ude. Nu Liam det tolkes som et evt våben imod
fjendtlig overtagelse, hvis rygterne er sande -
Top US Advisors (side 5)
BASED ON US ANNOUNCED DEALS – RANKED BY TRANSACTION VALUE: YTD 2023
Centerview Partners LLC som nummer 1 efterfulgt af JPMorgan Chase & Co og Goldman Sachs & Co.
https://go.factset.com/hubfs/mergerstat_em/monthly/US-Flashwire-Monthly.pdf
-
Det her bliver drama fra i morgen tidlig.
-
Jeg syntes særlig at en sætning er værd at bemærke “ The process may end up leading to a full sale of the company, which has previously been studied by large pharmaceutical firms, they said.”. - hvilket har været studeret tidligere. Hmmm - så er der nogen som allerede cirkler.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind